Dataset Information

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

ABSTRACT: PURPOSE:The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS:This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. RESULTS:The survival rate at 24 months was 57.2% (95% CI 51.0-62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45-3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients' tumors with the luminal A subtype had a significantly better objective response rate. Kaplan-Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p?

SUBMITTER: Rau KM

PROVIDER: S-EPMC6022524 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

Rau Kun-Ming KM Ou-Yang Fu F Chao Ta-Chung TC Kuo Yao-Lung YL Cheng Tsui-Fen TF Chao Tsu-Yi TY Chen Dar-Ren DR Tzeng Yen-Dun YD Wang Being-Whey BW Liu Chun-Yu CY Hu Ming-Hung MH Lu Yin-Che YC Ou Wei-Jen WJ Kuo Chin-Ho CH Chuang Chieh-Han CH Kan Jung-Yu JY Chen Fang-Ming FM Hou Ming-Feng MF

Breast cancer research and treatment 20180405 3

<h4>Purpose</h4>The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer.<h4>Methods</h4>This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer.<h4>Results</h4>The survival rate at 24 months was 57.2% (95% CI 51.0-62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45-3.94). ...[more]

PMID: 29623575

Similar Datasets

Project description:BackgroundEribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim of this study was to determine the efficacy and safety profile of eribulin and explore potential predictive factors for the efficacy of eribulin among Chinese women with metastatic breast cancer (MBC) in real-world practice.Patients and methodsA total of 272 consecutive MBC patients who were treated with eribulin between November 2019 and October 2020 in 9 institutions nationwide were included in this study. Eribulin was administered intravenously at a dose of 1.4 mg/m2 on days 1 and 8 of a 21-day cycle. Efficacy outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). Adverse events (AEs) were graded according to The National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 5.0.ResultsEribulin showed a median PFS of 4.1 months (95% confidence interval [CI] 3.6-4.6); however, the OS data were immature. The ORR was 17.6% and the CBR was 24.6%. A total of 51.8% of patients received eribulin monotherapy, while 48.2% of patients were treated with eribulin plus targeted therapy or other chemotherapy. The number of metastatic sites, duration of previous taxane treatment for MBC, and combination with bevacizumab were significant in Cox multivariate analysis (p = 0.023, p = 0.048, and p = 0.046, respectively) and were significantly associated with PFS of eribulin. The most common AEs with eribulin treatment were hematological toxicities, including neutropenia, leukopenia, and anemia.ConclusionEribulin was effective with a manageable toxicity profile in clinical practice. Furthermore, when prescribed in combination with other agents, eribulin did not increase the toxic effects of each agent. Eribulin monotherapy or plus other agents is an alternative for the heavily pretreated patients with MBC.

Dataset Information

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

Publications

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets